Histrelin (Implant)

Introduction Overview

Generic Name

histrelin (implant)

Brand Name

Supprelin LA, Supprelin, Vantas

Dosage Form

subcutaneous implant (50 mg)

Drug Class

Gonadotropin releasing hormones, Hormones / antineoplastics

Pharmacokinetics

Absorption:
Histrelin is administered exclusively as a subcutaneous implant designed for sustained release of the active drug over a prolonged period, typically 12 months. The implant is inserted under the skin, most commonly in the inner aspect of the upper arm, from where histrelin is gradually released into the systemic circulation. Due to the implant formulation, absorption is controlled and slow, maintaining steady plasma concentrations without the peaks and troughs typical of immediate-release formulations. This delivery system allows for consistent hormone suppression and improved patient compliance. As a peptide, oral bioavailability is negligible; therefore, subcutaneous administration via implant is necessary to ensure adequate systemic exposure.

Distribution:
Once absorbed, histrelin distributes throughout the body via systemic circulation. It has a moderate volume of distribution compatible with its role as a hypothalamic releasing hormone analog. Being a large peptide molecule, histrelin does not readily cross the blood-brain barrier but acts on the pituitary gland to modulate hormone secretion. Plasma protein binding is limited due to its peptide nature. Distribution is primarily confined to extracellular fluid, with minimal accumulation in tissues. The implant achieves steady-state plasma levels sufficient to downregulate gonadotropin release from the anterior pituitary through continuous receptor stimulation.

Metabolism:
Histrelin, as a synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH), undergoes proteolytic degradation primarily by endogenous peptidases in plasma and peripheral tissues. The metabolic pathways involve enzymatic cleavage of peptide bonds, leading to inactive fragments. This rapid metabolism of unbound histrelin necessitates the use of sustained-release implants to maintain therapeutic levels. The liver is not a major site of histrelin metabolism; rather, systemic peptidases effect clearance. No significant active metabolites have been identified that contribute to the drug’s pharmacologic effects.

Elimination:
The metabolites of histrelin, following proteolytic cleavage, are eliminated primarily via renal excretion. The intact drug does not accumulate due to its rapid enzymatic degradation. The elimination half-life of histrelin in plasma is short when administered in immediate-release form (minutes), but with the implant, the continuous release prolongs effective plasma levels over months. The implant design allows for a sustained release profile, reducing the need for frequent dosing. Clinical implications include dose adjustments being unnecessary in renal or hepatic impairment due to local release dynamics and absence of significant hepatic metabolism.

Dosage Forms

Available Dosage Forms:
Histrelin is available exclusively as a subcutaneous implant containing 50 mg of the active drug. This implant is designed for insertion under the skin of the inner upper arm. The implant releases histrelin steadily for approximately 12 months before requiring removal and potential replacement for continued therapy. There are no oral, intravenous, or other dosage forms approved for clinical use.

Dosages for Adults and Adolescents:
For adult men, particularly those with advanced prostate cancer, a single 50 mg histrelin implant (brand name Vantas) is inserted subcutaneously once every 12 months. This provides continuous hormone suppression for the duration to palliate prostate cancer symptoms.

Dosages for Pediatric Patients:
In pediatric patients aged 2 years and older with central precocious puberty, the approved dose involves a single 50 mg implant (brand name Supprelin LA) subcutaneously implanted every 12 months. The duration and continuation of therapy are at the discretion of the physician, generally discontinued at the appropriate physiological onset of puberty (~11 years for females, ~12 years for males).

Specific Patient Populations:
- Pediatrics: Supprelin LA is indicated for children aged 2 years and older; not recommended for children under 2 years.
- Adults: Vantas implant is indicated for adult men only and is contraindicated in women and children.
- Special populations: No specific dose adjustment is commonly required because of the implant delivery system. However, patients with mental illness, seizure disorders, or other neurologic conditions should be monitored closely due to known CNS effects.

Clinical Guidelines:
The implant is placed by a healthcare provider via minor surgical procedure using local anesthesia, with insertion preferably on the non-dominant arm to minimize patient discomfort during healing and procedure care. Patients should avoid strenuous activity and arm heavy lifting for approximately 7 days post insertion. The implant typically remains in situ for 12 months and must be surgically removed by a healthcare professional; self-removal is contraindicated. Replacement implants may be inserted immediately following removal for ongoing treatment. Regular monitoring of clinical status is advised to determine treatment duration.

Mechanism Of Action

Histrelin is a potent synthetic analog of gonadotropin-releasing hormone (GnRH), a decapeptide that acts as a neurohormone synthesized by the hypothalamus. Upon administration via the subcutaneous implant, histrelin achieves sustained stimulation of GnRH receptors located on the anterior pituitary gonadotroph cells. Initially, this leads to increased secretion of the gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH), resulting in a transient rise in sex steroid synthesis by the gonads.

However, due to its continuous receptor stimulation, histrelin induces receptor desensitization and downregulation over time, leading to suppression of LH and FSH secretion. This phenomenon, known as downregulation of the hypothalamic-pituitary-gonadal axis, results in decreased production of sex steroids such as testosterone and estradiol. This mechanism allows histrelin to effectively reduce the hormonal stimuli responsible for the progression of hormone-dependent conditions such as central precocious puberty in children and advanced prostate cancer in adult men.

At the cellular level, histrelin binds with high affinity to GnRH receptors (a G-protein coupled receptor) on pituitary gonadotrophs. Continuous ligand exposure leads to internalization and reduced receptor expression or sensitivity, interrupting the normal pulsatile GnRH signaling required for gonadotropin synthesis. This biochemical interaction translates clinically into hypogonadotropic hypogonadism, effectively controlling disease manifestations related to sex hormone excess or inappropriate production.

Comparatively, histrelin shares its mechanism with other GnRH agonists such as leuprolide, triptorelin, and nafarelin, but the subcutaneous implant formulation provides prolonged continuous drug exposure without the need for frequent injections. Multiple clinical studies have demonstrated that histrelin provides effective, steady suppression of sex steroids with good tolerability, leading to improved management of central precocious puberty and prostate cancer symptoms. Research continues into optimizing implant duration and evaluating long-term safety in various populations.

Pharmacological Actions

Continuous GnRH receptor agonist activity resulting in an initial stimulation followed by suppression of LH and FSH secretion.
Downregulation and desensitization of pituitary GnRH receptors due to sustained receptor activation.
Decreased gonadal steroidogenesis resulting in lowered serum testosterone and estradiol levels.
Suppression of hypothalamic-pituitary-gonadal axis activity, inducing a reversible hypogonadal state.
Reduction of puberty progression markers in children with central precocious puberty.
Palliative decrease of androgen-driven prostate cancer symptoms by reducing circulating testosterone.
Long-acting effect due to slow release from subcutaneous implant stability.
Minimal systemic fluctuations in hormone levels due to sustained implant dosing.
Non-oral peptide drug circumventing first-pass metabolism.
Modulation of hormone-dependent tissues by limiting sex steroid availability.
Potential influence on central nervous system mood and behavior through hormonal modulation.
Reduction in bone turnover secondary to sex steroid suppression.
Suppression of ovulation and menstrual cyclicity in sex hormone-dependent conditions.

Therapeutic Or Clinical Uses

Treatment of central precocious puberty in children aged 2 years and older to delay premature puberty development.
Palliative therapy for advanced prostate cancer symptoms by reducing testosterone levels.
Management of hormone-dependent conditions requiring suppression of gonadotropins.
Off-label use in certain hormone-sensitive neoplasms under clinical discretion.
Use as part of assisted reproductive technology protocols for pituitary downregulation.
Investigation as an adjunct for endometriosis and uterine fibroids (not primary indication).
Potential use in sexual hormone modulation therapies under specialist supervision.
To prevent premature epiphyseal closure in children by decelerating puberty onset.
Reduction of testosterone-driven prostate cancer growth facilitating symptom control.
Temporizing therapy in pediatric patients unsuitable for other interventions.
Suppression of pubertal progression in children with developmental delays.
Adjunctive therapy for certain hormone-responsive tumors within investigational settings.

Side Or Adverse Effects

Injection site reactions including pain, redness, bruising, swelling, or skin irritation at the implant site.
Constipation occurring as a common gastrointestinal side effect.
Urinary difficulties including painful or difficult urination.
Breast swelling or tenderness noted particularly in pediatric patients.
Hot flashes due to hypoestrogenism or hypoandrogenism from hormone suppression.
Fatigue or feelings of tiredness related to systemic hormonal changes.
Erectile dysfunction and decreased testicular size in adult male patients receiving therapy.
Potential for increased intracranial pressure causing headaches, dizziness, nausea, vision disturbances.
Neuropsychiatric symptoms including mood changes, crying spells, anger, aggression, restlessness, or irritability.
Bone pain or neurological symptoms such as numbness or weakness in extremities.
Potential allergic reactions manifesting as hives, facial swelling, or breathing difficulties.
Possible seizure activity or exacerbation of seizure disorders.
Transient initial exacerbation of precocious puberty signs within the first week of implantation.
Risk of implant extrusion or displacement requiring medical attention.

Precautions

Do not use in patients with known hypersensitivity to histrelin or other GnRH analogs such as leuprolide or nafarelin.
Avoid use during pregnancy due to risk of fetal harm and pregnancy loss; employ effective contraception.
Not recommended for use in children under 2 years of age.
Vantas implant contraindicated in women and children; Supprelin LA indicated for pediatric use only.
Monitor patients with history of mental illness, seizures, or neurological disorders due to potential CNS adverse effects.
Use caution in patients with bladder obstruction, diabetes, cardiovascular disease, or prolonged QT syndrome.
Patients with low bone mineral density or osteoporosis should be monitored due to risk of bone loss.
Insertion site should be carefully monitored for signs of infection, inflammation, or implant displacement.
Avoid strenuous physical activity or heavy lifting with the arm bearing the implant for at least 7 days post insertion.
Regular follow-up to assess therapy efficacy and to determine timing for implant removal or replacement.
Inform all healthcare providers about histrelin use when undergoing medical testing, as it may influence certain laboratory results.
Careful consideration recommended before starting or continuing therapy in patients with malignancies other than prostate cancer or precocious puberty.
Patients with epilepsy or seizure disorders should be closely monitored during treatment.
Caution in breastfeeding women; insufficient data regarding safety in lactation.

Warnings

Histrelin can cause fetal harm and should not be used during pregnancy; category X risk.
Potential for neuropsychiatric adverse effects including crying spells, irritability, aggression, and mood disturbances; immediate medical consultation advised if symptoms occur.
Increased intracranial pressure has been reported; symptoms such as severe headache, visual disturbances, nausea, and dizziness warrant prompt evaluation.
Risk of implant site complications including extrusion, infection, or localized reactions necessitating medical evaluation.
Use in patients with seizure disorders may exacerbate seizures.
Therapy may cause bone mineral density reduction; consider monitoring and preventative measures for osteoporosis.
Not effective for prostate cancer itself but only for symptom palliation; alternative definitive therapies should be considered.
Discontinuation of treatment should be guided by clinical criteria and onset of physiological puberty.
Pregnancy prevention measures should be strictly enforced due to teratogenic risk.
Mental health status should be evaluated before and during therapy to promptly address emerging psychiatric effects.
Patients should be informed that initial transient increase in puberty symptoms may occur post-implantation.
Implant must be removed surgically after approximately 12 months to avoid local complications and maintain therapeutic efficacy.
Avoid self-removal or tampering with the implant to prevent injury or infection.
Laboratory test interference possible; patients should inform clinicians to avoid misinterpretation.

Contraindication

Known hypersensitivity to histrelin or other GnRH analogs.
Pregnancy or suspected pregnancy due to potential teratogenicity and risk of miscarriage.
Use of Vantas implant in females or pediatric patients under 18 years.
Patients with active severe psychiatric disorders uncontrolled or exacerbated by hormonal modulation.
Severe uncontrolled seizure disorders without appropriate management.
Hypersensitivity reactions to implant components or excipients.
Use in children under 2 years old for Supprelin LA.
Presence of infections at proposed implant site.
Patients with a history of severe allergic or anaphylactic reactions to GnRH analog medications.
Conditions requiring immediate restoration of gonadal function or fertility.
Patients with prolonged QT syndrome should avoid this medication due to risk of arrhythmia exacerbation.
Known malignancies other than prostate cancer or conditions where suppression of gonadal hormones is contraindicated.
Severe hepatic or renal impairment requiring alternate therapeutic strategies.
Prior failure to respond to GnRH analog therapy.

Drug Interactions

Concomitant use with other hormonal therapies may alter efficacy or increase side effects.
Drugs that lower seizure threshold (such as certain antidepressants and antipsychotics) may potentiate neuropsychiatric adverse effects.
Medications affecting QT interval may increase risk of arrhythmias when combined with histrelin.
Concomitant use with corticosteroids may exacerbate bone loss.
Co-administration with drugs metabolized by peptidase enzymes unlikely to cause interaction due to localized degradation of histrelin.
Drugs influencing pituitary or hypothalamic function may alter histrelin's pharmacodynamics.
Potential interaction with anticoagulants or antiplatelet drugs due to surgical implant insertion procedure.
Herbal supplements affecting hormonal balance (e.g., phytoestrogens) may interfere with therapeutic effects.
Concomitant use with chemotherapeutic agents requires monitoring for additive endocrine effects.
Interaction with diabetes medications possible due to histrelin’s impact on metabolic pathways.
No significant cytochrome P450 enzyme interactions anticipated due to peptide nature and route of administration.
Co-administration with CNS depressants may augment fatigue or drowsiness.
Patients should inform all prescribing physicians of histrelin implant to avoid unanticipated interactions.
Interactions with over-the-counter supplements and vitamins should be reviewed by healthcare providers.

Preparations Of The Drug

Histrelin acetate subcutaneous implant containing 50 mg active drug formulated for prolonged release.
Sterile implant designed for insertion via minor surgical procedure under local anesthesia.
Implant composed of biocompatible materials to minimize immunogenicity and rejection.
Packaging includes sterile insertion tools appropriate for subcutaneous placement.
Implants typically supplied pre-loaded and ready for immediate clinical use.
Designed for single-use only; non-reusable implant and insertion device.
Storage recommendations include protection from moisture and controlled room temperature conditions.
Preparation requires trained healthcare provider for insertion and removal procedures.
Supplied under brand names: Supprelin LA (for pediatric precocious puberty) and Vantas (for prostate cancer).
No oral or alternative formulations currently approved; implant is sole commercial route.
Recommended disposal procedures for used implants and insertion kits respecting biomedical waste protocols.
Patient information includes guidance on activity restrictions post-insertion and monitoring of insertion site.
Implants manufactured under Good Manufacturing Practices ensuring consistent drug release profiles.
Supplemental materials include surgical strips or sutures to close implantation site.